BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced that it has engaged Charles River Associates (CRA) (NASDAQ:CRAI) and Kaleio, Inc. to support commercial strategy, market access evaluation and brand planning for Bria-IMT.

Bria-IMT is currently being evaluated in BriaCell’s ongoing pivotal Phase 3 study (ClinicalTrials.gov identifier: NCT06072612) in metastatic breast cancer and is not a commercially approved therapy. These engagements represent a prudent commercial-readiness step as BriaCell continues to evaluate BRIA-IMT and prepares for potential future commercialization planning and strategic discussions, subject to successful clinical development and applicable regulatory approvals.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.